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Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease that
affects the neurons of the central nervous system. Activated T cells, specific for myelin
epitopes, cross the brain barriers, and react against the myelin sheath, leading to
demyelination. Since T cells are generated within the thymus, here we explored, in
mice, the alterations occurring in this organ throughout the different phases of the
disease. We induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6
females and sacrifice them at the onset (day 16) and chronic phases of disease
(day 23), along with non-induced controls. We observed thymic atrophy in EAE mice
at the onset that remained until the chronic phase of disease. This atrophy was
associated with a preferential loss of the CD4+CD8+ double positive thymocytes, an
intermediate population between the more immature CD4−CD8− double negative and
the most mature single positive thymocytes. This was accompanied by an increase
in the thymic medullary/cortical ratio and by an altered expression levels of genes
important for T cell survival. During the chronic phase, the thymi remained atrophic, but
reacquired the normal proportion of the main four thymocyte populations and the normal
medullary/cortical ratio. Importantly, at the onset phase, and accompanying these thymic
alterations, EAE animals presented an increased percentage of demyelinating lesion area
in the cerebellum, and an increased expression of interferon gamma (Ifng), interleukin (Il)
12a, and Il17a. This study suggests dynamic thymic alterations occurring in response
to EAE, from the induction to the chronic phase, that might help to elucidate the MS
pathophysiology.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the central
nervous system (CNS) (1–3). Both environmental and genetic factors contribute for MS
development (4, 5), but the underlying pathophysiological and etiological mechanisms are
not completely understood. Currently, the animal model most widely used to study MS
is the experimental autoimmune encephalomyelitis (EAE) (6–8). In the EAE model, the
immunization of susceptible mice with myelin proteins induces autoimmunity against CNS
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components (6). Therefore, this model allows the study of
several mechanisms underlying the disease, such as immune
cell migration across blood-brain and blood-choroid plexus-
cerebrospinal fluid barriers (9, 10) and T cell activation upon
recognition of self-molecules (9). In addition, this model has been
used to study mechanisms to abrogate the pathological processes
involved in the development of MS, by using knockout models or
testing new potential therapies (9, 11).
The thymus is a primary lymphoid organ where bone marrow
derived progenitor cells undergo diﬀerentiation to originate
functional T cells (12). Moreover, the thymus is also central for
the control of organ-specific autoimmunity, both by limiting the
output of autoreactive T cells, via negative selection (13), and
by generating regulatory T cells (14). Concerning tolerance to
self, it is known that intrathymic expression of CNS proteins,
particularly by thymic epithelial cells (TECs), is important for
the establishment of T-cell tolerance to self (13, 15). In the
EAE model, it was shown that thymic epithelial expression
of proteolipid protein (PLP) contributes to T-cell tolerance
to PLP (16). Furthermore, the intrathymic administration of
myelin oligodendrocyte glycoprotein (MOG)-expressing thymic
epithelial progenitors induced specific tolerance against this
antigen and significantly reduced EAE severity (17, 18).
In the thymus, the four main thymocyte populations are
characterized by the surface expression of the co-receptor
molecules CD4 and CD8. The most immature population,
the CD4−CD8− double negative (DN) cells, diﬀerentiates to
CD4+CD8+ double positive (DP) cells, followed by thymocyte
relocation from the cortex to the medulla, and commitment to
either the CD4+ or CD8+ T cell lineage. After diﬀerentiation
in the thymic medulla, CD4+CD8− single positive (CD4SP)
and CD4−CD8+ single positive (CD8SP) thymocytes leave the
thymus and colonize the periphery (19). Although, the vast
majority of T cells are self-tolerant, i.e., do not become activated
upon encountering self-molecules, a defect in one or more of
the multiple mechanisms that control self-reactivity can lead to
breakdown of tolerance, ultimately resulting in T-cell mediated
autoimmune diseases, as it is the case for MS (20).
Previous work has demonstrated that thymectomy in
newborn mice prevented or markedly delayed the appearance of
EAE symptoms (21, 22), suggesting that T cells are required for
the production of signs and histological lesions. Also,MS patients
were shown to present decreased thymic output (23), indicating
that the thymic function could be altered in the disease. In this
work, to better understand the thymic alterations occurring in
response to EAE induction, we evaluated the main thymocyte
populations, the thymic histological morphology and thymic
gene expression in two disease time points, a more active phase
(onset phase) of disease and during the chronic phase.
MATERIALS AND METHODS
Animals
All experiments were reviewed and approved by the Portuguese
national authority for animal experimentation, Direcção Geral de
Veterinária (ID: DGV9457). Animals were housed and handled
in accordance with the guidelines for the care and handling of
laboratory animals in the Directive 2010/63/EU of the European
Parliament and the Council.
Animals were housed and maintained in a controlled
environment at 22–24◦C and 55% humidity, on 12 h light/dark
cycles (lights on at 8 a.m.) and fed with regular rodent chow and
tap water ad libitum.
EAE Induction and Experimental Groups
Disease was induced in 10–16 weeks of age female C57BL/6 mice,
using a commercial kit (EK-2110; Hooke Laboratories, Lawrence,
MA, USA) according to the manufacturer’s instructions. Briefly,
animals were immunized subcutaneously with 200 µg of
MOG35−55, emulsified in complete Freund’s adjuvant (CFA), at
the upper and lower back. Pertussis toxin (PTX) in phosphate
buﬀered saline (PBS) was administered intraperitoneally 2 and
24 h after immunization (227 ng of PTX per injection). Non-
induced age-matched littermate females were used as controls
and were injected subcutaneously with an emulsion of PBS in
CFA (Difco Laboratories, Detroit, USA), and with PTX (List
Biological Laboratories, Inc., Campbell, CA, USA) at the same
concentration and time points as the EAE animals. Animals were
daily weighted and monitored for clinical symptoms of disease.
Disease severity was assessed daily as previously described (24)
with few changes, as follows: 0 = no clinical symptoms; 0.5 =
partially limp tail; 1 = paralyzed tail; 1.5 = at least one hind
limb falls through consistently when the animal is placed on a
wire rack; 2 = loss in coordinated movement, wobbly walk; 2.5
= dragging of hind limbs; 3 = paralysis of both hind limbs;
3.5 = hind limbs paralyzed and weakness of forelimbs; 4 =
complete hind limbs paralysis and partial forelimbs paralysis; 4.5
= animal is not alert, nomovement; 5=moribund state or death.
Paralyzed mice, with clinical scores above 3, were oﬀered easier
access to food and water.
Tissue Sample Collection and Storage
For biological sample collection, both EAE and non-induced
animals were sacrificed, at the light phase of the diurnal cycle,
at days 16 (onset/peak phase; maximum average clinical score,
animals with scores 1.5–3.5) and 23 (chronic phase) after EAE
induction. Animals were anesthetized with an intraperitoneal
injection of ketamine hydrochloride (150 mg/kg, Imalgene R⃝
1000) plus medetomidine hydrochloride (0.3 mg/kg, Dorben R⃝).
Under deep anesthesia, mice were transcardially perfused with
cold 0.9% saline solution, and the thymus, brain and spinal
cord were dissected. For gene expression analysis by qRT-PCR,
cerebellum and thymus samples were snap-frozen and stored at
−80◦C. For histological analysis, the brain and spinal cord were
immediately embedded in Tissue-Tek R⃝ O.C.T.TM compound
(Sakura Finetek, Japan), snap-frozen and kept frozen until further
sectioning. 7µm frozen thymic sections were stained with
hematoxylin and eosin. For flow cytometry, thymi were placed in
3mL of Dulbecco’s Modified Eagle Medium (DMEM) with 10%
fetal bovine serum and further processed.
Flow Cytometry Analysis
Single-cell suspensions of thymi were prepared by mechanical
dissociation, and cell suspensions were centrifuged at 1,200
Frontiers in Immunology | www.frontiersin.org 2 October 2018 | Volume 9 | Article 2335
das Neves et al. Thymic Profile in EAE Mice
rotations per minute for 10min at 4◦C. After resuspending the
pellet in 2mL of FACS buﬀer (0.5% bovine serum albumin, 0.01%
azide in PBS buﬀer), the total number of cells was counted in the
MUSE R⃝ cell analyzer (Merck Millipore, Darmstadt, Germany),
after staining with 7-aminoactinomycin D (7-AAD) for 10min
on ice.
For flow cytometry analysis, cells were stained, for 20min
on ice, with Brilliant Violet 421 anti-mouse CD3 (clone 145-
2C11; BioLegend, San Diego, CA, USA), PercpCy5.5 anti-mouse
CD4 (clone RM4-5; BioLegend), and V500 anti-mouse CD8
(clone 53-6.7; BD Biosciences, Franklin Lakes, NJ, USA), washed
thoroughly and resuspended in 200 µL of FACS buﬀer. All
samples were acquired (minimum of 50000 events/sample) on
an eight-color BD LSRII flow cytometer using the FACS DIVA
software (BD Biosciences). Data was analyzed using the FlowJo
software (Tree Star, Ashland, OR, USA) version 10.0.8. The
gating strategy used is represented in Supplementary Figure 1.
Immunofluorescence for Cytokeratin (CK)
5 and CK8 in Thymus Sections
Serial 7µm sections of frozen thymus were cut in the cryostat,
collected to SuperFrost R⃝ Plus slides (ThermoFisher Scientific,
Waltham, MA, USA), and stained with CK5 (1:500; Abcam,
Cambridge, UK) and CK8 (1:500; Troma1, developed by P.
Brulet and R. Kemler and obtained from the Developmental
Studies Hybridoma Bank, developed under the auspices of the
National Institute of Child Health and Human Development
and maintained by the University of Iowa, Department of
Biology, Iowa City, IA), as previously described (25). Secondary
antibodies used were goat anti-rat IgG Alexa Fluor 594 (1:500;
Life Technologies, ThermoFisher Scientific) and goat anti-rabbit
IgGAlexa Fluor 488 (1:500; Invitrogen, ThermoFisher Scientific).
Slides were visualized using a fluorescence microscope (BX61
microscope; Olympus, Hamburg, Germany) and images were
posteriorly analyzed using the Fiji software (26). The total
CK5 and CK8 positive areas were measured after assembling
sequentially acquired images with the Fiji plugin “Stitching”
(27). A total of 2 cuts per animal were analyzed, in a blind
manner regarding the experimental group. Statistical analysis was
performed using the average of the 2 cuts of the animal.
Luxol Fast Blue Staining in Cerebellum and
Spinal Cord Sections
Serial 20µm sections of frozen cerebellum and spinal cord
were cut in the cryostat and collected to SuperFrost R⃝ Plus
slides (ThermoFisher Scientific) and were posteriorly stained
with Luxol Fast Blue. Briefly, sections were fixated in 95%
ethanol at room temperature for 15min. Next, slides were stained
in 0.1% Luxol Fast Blue MBS (Chroma-Gesellshaft Schmidt
GmbH&Co, Köngen, Germany) and 0.5% glacial acetic acid in
96% ethanol overnight at 56◦C. The excess of dye was removed
using first 96% ethanol, and then running tap water. Slides were
diﬀerentiated with 0.05% lithium carbonate (Sigma-Aldrich R⃝, St.
Louis, MO, USA) for 10min and with 70% ethanol for 1min.
After counterstaining with hematoxylin for 1min, slides were
washed with running water, left to dry on air, and mounted with
Entellan R⃝ (Merck Millipore).
The quantification of the total lesioned area was done in 6–8
non-consecutive sections representative of the entire cerebellum.
The sections were visualized with an Olympus microscope, and
the quantification of the areas was performed with the Stereo
Investigator software (MBF Bioscience, Williston, Vermont,
USA), in a blind manner regarding the disease time point and
group. The total whitematter area was drawn using a 4x objective,
and the lesion areas using the 10x objective. The percentage of
lesioned area, for each section, was calculated by dividing the sum
of the lesioned areas by the total white matter area. Statistical
analysis was performed using the average of all sections of the
animal.
Gene Expression Analysis by qRT-PCR
Total RNA was extracted from the cerebellum and the
thymus using TRIzol R⃝ reagent (Life Technologies) following
manufacturer’s instructions. RNA was quantified using the
NanoDrop R⃝ 1000 spectrophotometer (ThermoFisher Scientific)
and diluted to a final concentration of approximately 1
µg/µL. Next, 2-4 µg of total RNA were treated with DNase
I (Life Technologies), and 500 ng of total RNA from each
sample were reverse transcribed into cDNA using the iScriptTM
cDNA synthesis kit (BioRad Laboratories, Hercules, CA, USA),
according to the manufacturer’s instructions. Primers used to
measure the expression levels of selected mRNA transcripts
by qRT-PCR were designed using the Primer-BLAST tool of
the National Center for Biotechnology Information (Bethesda,
MD, USA) on the basis of the respective GenBank accession
numbers. All GenBank accession numbers for Mus musculus
gene transcripts and primer DNA sequences are provided in
Supplementary Table 1. The qRT-PCR was performed on a
CFX96TM real-time instrument (BioRad) with the SsoFastTM
EvaGreen R⃝ Supermix (BioRad), according to the manufacturer’s
instructions using equal amounts of cDNA from each sample.
The cycling parameters were 1 cycle at 95◦C, for 1min, followed
by 40 cycles at 95◦C for 15 s, annealing temperature (primer
specific) for 20 s and 72◦C for 20 s, finishing with 1 cycle at
65◦C to 95◦C for 5 s (melting curve). Product fluorescence was
detected at the end of the elongation cycle. All melting curves
exhibited a single sharp peak at the expected temperature. 18S
ribosomal RNA (18S), Adenosine Triphosphate subunit 5 beta
(Atp5b), and Heat Shock Protein 90 alpha family class B member
1 (Hspcb) were used as reference genes (28).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.01
(GraphPad software Inc., La Jolla, CA, USA). One animal injected
withMOG35−55/CFA emulsion was excluded from all the analysis
due to absence of clinical symptoms of disease by the endpoint of
the experiment. Sample normality distribution was tested using
the Shapiro-Wilk (n > 6) and the Kolmogorov-Smirnov (n ≤ 6)
normality tests.
For the comparison between EAE onset and EAE chronic,
a two-tailed unpaired t-test was used, and the Cohen’s d was
calculated as a measure of eﬀect size (29)—0.2, 0.5, and 0.8 were
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considered as small-, medium- and large-eﬀect size, respectively
(30). The non-induced, EAE onset and EAE chronic groups
were compared using the parametric one-way ANOVA with
Tukey’s multiple comparison post-hoc test, for samples with
normal distribution, or the non-parametric Kruskal-Wallis with
Dunn’s multiple comparison post-hoc test, for samples without
normal distribution. To quantify the strength of the diﬀerences,
the eta-squared value (η2) was calculated as a measure of
eﬀect size (29)—0.01, 0.06, and 0.14 were considered as small-,
medium- and large-eﬀect size, respectively (30). For correlations,
the Pearson correlation coeﬃcient or the Spearman’s rank
correlation coeﬃcient were used for samples with normal
distribution or samples without normal distribution, respectively.
The strength of the correlations were quantified using the r
squared.
Results are presented as mean ± standard error of
mean (SEM), for parametric statistical tests, or median and
interquartile range (IQR), for non-parametric statistical tests,
and as the average of the experiments performed. The number
of biological replicates (n) and of independent experiments are
specified in the legend of each figure. Statistical significance was
considered for p < 0.05 (∗), p < 0.01 (∗∗), p < 0.001 (∗∗∗), p <
0.0001 (∗∗∗∗).
RESULTS
EAE Induction Triggered Thymic Atrophy
Upon EAE induction following the protocol described previously
(31), animals developed a chronic disease, as expected. By day
11 post-disease induction, EAE animals started to lose weight
(Supplementary Figure 2A) and to present clinical symptoms of
disease (Supplementary Figure 2B). On day 16 (onset phase of
disease), most animals had lost around 20% of their initial weight
(Supplementary Figure 2A) and had reached an average clinical
score of 3, which was maintained until day 23 (chronic phase of
disease) (Supplementary Figure 2B).
We observed that EAE mice presented severe thymic atrophy,
at both the onset and chronic phases, as assessed by a decrease
in the thymus weight [Figure 1A; χ2(2) = 9.42, p = 0.0024, η
2 =
0.618]. This decrease was not related to the body weight loss, as
it was measured after normalizing the thymic weight for the total
body weight [Figure 1B; F(2, 12) = 46.48, p< 0.0001, η2 = 0.886].
In agreement, the total thymocyte number [Figure 1C; χ2(2) =
26.66, p< 0.0001, η2 = 0.616], as well as the percentage of viable
cells [Figure 1D; F(2, 40) = 7.914, p = 0.0013, η2 = 0.284] were
reduced in both time points.
Thymic Atrophy Following EAE Induction
Was Associated With a Preferential Loss of
the Immature DP Thymocytes
The proportion of the four main thymocyte populations was
drastically altered at the onset, but not at the chronic phase of
disease (representative CD8 vs. CD4 plots in Figure 2A). More
specifically, EAE animals at the onset phase presented lower
percentages of DP cells, and consequently higher percentages
of DN, CD4SP, and CD8SP cells (Figure 2B). Of interest, in
the chronic phase, the thymocyte populations were reestablished
to the control proportions [Figure 2B; DN–χ2(2) = 24.12, p <
0.0001, η2 = 0.553; DP–χ2(2) = 21.65, p < 0.0001, η
2 = 0.491;
CD4SP–χ2(2) = 22.71, p < 0.0001, η
2 = 0.518; CD8SP–χ2(2) =
21.17, p< 0.0001, η2 = 0.479].
Reflecting the observed decrease in total cell numbers, the
absolute numbers of the main thymocyte populations were
decreased at both the onset and chronic phases of disease
[Figure 2C; DN–χ2(2) = 13.87, p= 0.001, η
2 = 0.297; DP–χ2(2) =
27.79, p < 0.0001, η2 = 0.645; CD4SP–χ2(2) = 24.93, p < 0.0001,
η
2 = 0.573; CD8SP–χ2(2) = 20.93, p< 0.0001, η
2 = 0.473].
Remarkably, at the onset phase of EAE, the percentage of DP
thymocytes was inversely correlated with the clinical score of the
animals on the day of sacrifice (Figure 2D; Spearman r=−0.647,
p = 0.0071, r2 = 0.419). On the other hand, the percentages of
CD4SP and CD8SP populations were directly correlated with the
animals’ clinical score (Figure 2D; CD4SP–Spearman r = 0.531,
p= 0.0535; CD8SP–Pearson r = 0.700, p= 0.0054, r2 = 0.489).
Altered Medullary/Cortical Ratio and Gene
Expression in the EAE Onset
To investigate to what extent the thymic structure was also
aﬀected during EAE, we performed an hematoxylin and eosin
histochemical staining (Figure 3A). We confirmed, at the
histological level, that EAE animals presented thymic atrophy,
and it was possible to observe a decrease in the cortical layer at
the onset phase of disease. To confirm this, we next performed
a double staining for CK5 and CK8, which are preferentially
expressed in thymic epithelial medullary and cortical cells,
respectively (Figure 3B), and quantified the ratio between the
medullary and cortical layers. As expected, since DP thymocytes
are mostly present in the cortex and the proportion of these cells
is severely aﬀected in the onset, we observed an increase in the
medullary/cortical ratio at the onset, but not at the chronic phase
of EAE [Figure 3C; χ2(2) = 10.11, p= 0.0012, η
2 = 0.624].
We next quantified the expression levels of genes important
for thymocyte diﬀerentiation and survival, and also of genes
relevant in the EAE context. We found a significant increase
in the expression levels of interleukin (Il) 7 in EAE animals
[Figure 4A; χ2(2) = 14.85, p< 0.0001, η
2 = 0.676]. IL-7 signaling
promotes cell survival by inducing expression of anti-apoptotic
genes such as B-cell lymphoma 2 (Bcl2), which we also found
increased in the thymus of EAE animals [Figure 4B; χ2(2) =
15.10, p < 0.0001, η2 = 0.728]. Moreover, we observed that
the expression levels of transforming growth factor beta 1
(Tgfb1), which presents an anti-apoptotic role in thymocytes,
were increased in the onset phase [Figure 4C; F(2,19) = 5.36, p
= 0.0142, η2 = 0.361]. B-cell lymphoma/leukemia 11B (Bcl11b),
which is involved in the positive selection and survival of DP
thymocytes (32), was not altered in EAE animals [Figure 4D;
F(2,19) = 2.53, p = 0.1063]. IL-6 and tumor necrosis factor alpha
(TNFa) were previously associated with thymic atrophy, and
their gene expression was increased in EAE animals at the onset
phase of disease [Figures 4E,F; Il6–χ2(2) = 8.75, p= 0.0064, η
2 =
0.375; Tnfa–χ2(2) = 10.20, p = 0.0019, η
2 = 0.456]. In addition,
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FIGURE 1 | Thymic atrophy occurred after EAE induction. EAE animals, both at the onset and chronic phases, presented decreased absolute (A) and relative thymus
weight (B) compared with non-induced animals (1 independent experiment; Kruskal-Wallis with Dunn’s post-hoc test for absolute weight; one-way ANOVA with
Tukey’s post-hoc test for relative weight; n = 5/group). EAE animals, at the onset and chronic phases, presented a decreased total number of thymocytes (C) and a
decreased percentage of viable thymocytes (D), measured upon staining with 7-AAD (2 independent experiments; Kruskal-Wallis with Dunn’s post-hoc test for total
thymocyte number; one-way ANOVA with Tukey’s post-hoc test for percentage of viable thymocytes; nnon−induced = 19, nEAEonset = 14, nEAEchronic = 10). Data is
presented as mean ± SEM, for parametric statistical tests, or median ± IQR, for non-parametric statistical tests. *p < 0.05, **p < 0.01, ****p < 0.0001.
the thymic expression of pro-inflammatory cytokines relevant
for the disease such as interferon-gamma (Ifng) [Figure 4G;
χ
2
(2) = 7.18, p = 0.0200, η
2 = 0.288] and Il17a [Figure 4H;
χ
2
(2) = 13.44, p < 0.0001, η
2 = 0.636] were increased in
EAE animals, compared to non-induced animals. The anti-
inflammatory cytokine Il10 presented increased expression levels
at the onset and chronic phases of disease [Figure 4I; χ2(2) =
14.53, p < 0.0001, η2 = 0.696]. Inducible nitric oxide synthase
(Inos) was also found up-regulated in EAE animals in both
disease time points [Figure 4J; χ2(2) = 13.94, p < 0.0001, η
2 =
0.663]. For themajority of genes quantified, the increase observed
at the chronic phase was less pronounced than the one observed
at the onset phase.
The Cerebellum Exhibited a Different
Inflammatory Response in the EAE Onset
and Chronic Phases
Previous studies have shown that the cerebellum is aﬀected
in EAE (33–35), therefore, and to find correlates with the
peripheric thymic alterations, we investigated the expression of
T-cell associated cytokines in this region. At the onset phase, we
observed an increase in the expression levels of pro-inflammatory
cytokines associated with Th1 and Th17 cells, respectively Ifng
and Il17a [Figures 5A,B; Ifng–χ2(2) = 12.51, p < 0.0001, η
2 =
0.808; Il17a–χ2(2) = 12.04, p < 0.0001, η
2 = 0.772]. In addition,
Il12a, involved in the induction of a Th1 response, was also
increased at the onset phase [Figure 5C; χ2(2) = 9.96, p = 0.0016,
η
2 = 0.612]. At the chronic phase of disease, the expression levels
of these cytokines returned to control levels (Figures 5A–C). Il4
expression, a cytokine associated with Th2 cells, was increased
at the chronic phase of EAE, compared to the onset phase
[Figure 5D; F(2,13) = 8.34, p= 0.0047, η2 = 0.562].
After staining with Luxol Fast Blue (Figure 5E), lesion areas
in the white matter were identified by a paler blue staining
(or absence of staining) and by the presence of inflammatory
infiltrates (arrows on right bottom panel of Figure 5E). The total
area occupied by these lesions was quantified, and at day 16 post-
EAE induction, known to be the most active/severe phase of
disease, animals displayed a significant increase in total lesioned
area when compared with the chronic phase (day 23 post-EAE
induction) [Figure 5F; t(20) = 2.461, p = 0.0231, d = 1.224].
Moreover, during the onset phase, the percentage of lesioned
area was positively correlated with the clinical score of animals
[Figure 5G; Pearson r = 0.754; p = 0.0018; r2 = 0.568]. EAE
animals also presented lesioned areas in the spinal cord’ white
matter (Supplementary Figure 3).
DISCUSSION
Herein, we analyzed, in the EAE chronic model, the thymic
alterations in two important disease time points—onset and
chronic phases. In both, we observed thymic atrophy, assessed
by decreased thymic weight and total cell numbers. However,
the pattern of thymic atrophy was distinct in the two EAE
phases: while at the onset the percentage of DPs is extremely
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FIGURE 2 | Thymocyte proportions are altered in EAE animals during the onset but not the chronic phase of disease. Flow cytometry was performed in thymic
suspensions of non-induced and EAE animals, at the onset (16 days) and chronic (23 days) phases of disease, after staining with anti-CD3, anti-CD4 and anti-CD8
antibodies. Representative dot-plots of each experimental group (A). During the onset phase of disease, EAE animals presented a decrease in the percentage of DP
cells, and a consequent increase in the percentages of DN and SP populations (CD4SP and CD8SP); the percentages of these populations were restored to the levels
of non-induced animals at the chronic phase of disease (B). The absolute numbers of the evaluated thymocyte populations were decreased in EAE animals, during
the onset and chronic phases of disease (C) (2 independent experiments; Kruskal-Wallis with Dunn’s post-hoc test; nnon−induced = 19, nEAEonset = 14, nEAEchronic
= 10). At the onset phase of disease, the percentage of DP thymocytes was negatively correlated with the clinical score of the animals on the day of sacrifice, while
the percentages of CD4SP and CD8SP thymocytes were positively correlated with the clinical score (D) (2 independent experiments; Spearman correlation for DP vs.
clinical score and CD4SP vs. clinical score, Pearson correlation for CD8SP vs. clinical score; n = 14). Data presented as median ± IQR. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.
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FIGURE 3 | The thymic medullary/cortical ratio was altered at the onset phase of EAE. Representative thymic sections stained with hematoxylin and eosin (A) (scale
bar indicates 300µm). Thymic section evidencing medullary epithelial cells in green (CK5+) and cortical epithelial cells in red (CK8+) (B) (scale bar indicates 300µm).
The medullary/cortical ratio was increased in EAE animals during the onset, but not the chronic phase of disease (C) (1 independent experiment; Kruskal-Wallis with
Dunn’s post-hoc test; nnon−induced = 6, nEAEonset = 5, nEAEchronic = 5). Data presented as median ± IQR. *p < 0.05, **p < 0.01. C, cortical layer; M, medullary
layer.
FIGURE 4 | The expression levels of pro-inflammatory cytokines and of genes important for DP thymocyte differentiation and survival were altered during EAE. The
expression levels of Il7 (A), Bcl2 (B) and Tgfb1 (C) were increased in the thymus of EAE animals, while Bcl11b was not altered (D). The thymic expression levels of Il6
(E), Tnfa (F), the pro-inflammatory cytokines Ifng (G) and Il17a (H), the anti-inflammatory cytokine Il10 (I) and Inos (J) were also increased in EAE animals (1
independent experiment; Kruskal-Wallis with Dunn’s post-hoc test for Il7, Bcl2, Ifng, Il17a, Il10, Il6, Inos and Tnfa one-way ANOVA with Tukey’s post-hoc test for
Bcl11b and Tgfb1; nnon−induced = 11, nEAEonset = 6, nEAEchronic = 4 for Bcl2, Ifng, Il17a, Il10, Il6, Inos and Tnfa, nnon−induced = 11, nEAEonset = 6, nEAEchronic =
5 for Il7, Tgfb1 and Bcl11b). Data presented as mean ± SEM, for parametric statistical tests, or median ± IQR, for non-parametric statistical tests. *p < 0.05, **p <
0.01.
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FIGURE 5 | Distinct inflammatory profile in the cerebellum at the onset and chronic phases of disease. At the onset phase of disease, EAE animals presented an
increased expression of the pro-inflammatory cytokines Ifng (A), Il17a (B) and Il12a (C), compared to non-induced animals. The expression levels of the Th2 cytokine
Il4 were altered in chronic EAE animals compared to the onset phase of disease (D) (1 independent experiment; one-way ANOVA with Tukey’s post-hoc test for Il4,
Kruskal-Wallis with Dunn’s post-hoc test for remaining genes; nnon−induced = 5, nEAEonset = 6, nEAEchronic = 5). The Luxol Fast Blue staining evidenced lesion
areas, characterized by inflammatory infiltrates and lighter blue staining, in the cerebellum’ white matter of EAE animals (arrows, E right bottom panel), which were not
present in non-induced animals (E left panel) (scale bars indicate 200µm for lower magnification, and 50µm for higher magnification). EAE animals presented a
significant increase in the percentage of lesioned area at the onset phase of disease, compared with the chronic phase (F) (2 independent experiments; unpaired t
test; nEAEonset = 14, nEAEchronic = 8). At the onset phase of disease the percentage of lesioned area correlated positively with the clinical score (G) (2 independent
experiments; Pearson correlation, n = 14). Data presented as mean ± SEM, for parametric statistical tests, or median ± IQR, for non-parametric statistical tests.
*p < 0.05, **p < 0.01. GL, granular layer; ML, molecular layer; WM, white matter.
reduced, in the chronic phase all thymocyte populations are
equally reduced in number and the proportions of the four main
populations is re-established. Notably, these alterations in the
thymus were associated with inflammation in the CNS. Namely
in the cerebellum, at the onset phase, animals presented an
increased percentage of lesion sites and expression levels of pro-
inflammatory cytokines, which was no longer observed at the
chronic phase. Moreover, in the cerebellum we found that Il4
expression was increased at the chronic phase. Of relevance, the
intrathecal injection of an IL-4-expressing viral vector, after EAE
induction, was shown to significantly decrease disease severity,
reduce demyelination and axonal damage and also to increase
the percentage and absolute numbers of Foxp3+ Treg cells, in
the CNS (36). In accordance, the increase in Il4 expression, in
the cerebellum, might represent a recovery mechanism possibly
associated with a decrease in the local pro-inflammatory response
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and increased recruitment of Treg cells. Also, in EAE animals, it
was shown a gradual increase in the thymic production of Treg
cells from the onset to the chronic phase (37).
Of interest, altered thymic activity had already been suggested
in relapse-remitting MS patients (23) and thymic atrophy was
also found in other MS models, namely the cuprizone model
(38), in A.SW mice with primary-progressive EAE (39) and also,
recently, in rat EAE models (40). Herein we also showed thymic
atrophy accompanied by decreased percentage of viable cells, that
could result from apoptotic cell death, as observed in the rat EAE
models (40).
Here we found that, regarding the main thymocyte
populations, the onset phase was associated with a 70%
decrease of DP thymocyte percentage and a 90% of total DP
thymocytes, compared to non-induced animals. In accordance,
a previous study described a similar decrease of DP thymocytes
in an EAE model induced with recombinant MOG, at day 18
post-disease induction (39). In addition, we also show here
that at the chronic phase, the number of CD4SP and CD8SP
thymocytes was even further decreased and the total number
of DP thymocytes increased by 40%, when compared to the
onset phase, contributing for the normalization of the thymocyte
proportions.
Distinct mechanisms underlying the observed thymic
atrophy may occur. Depending on their levels, glucocorticoids
were found to play both positive and negative eﬀects on
thymocytes—low levels are associated with thymocyte survival
and proliferation, and high levels induce thymocyte apoptosis
(41). Moreover, glucocorticoids present immunosuppressive
properties, and have been used in the treatment of several
inflammatory and autoimmune pathologies, including MS
(42). Nevertheless, elevated concentrations of glucocorticoids
were shown to trigger severe thymic atrophy, mainly by
inducing DP thymocytes apoptosis (43). Of interest, a previous
study has found a progressive decrease in thymic weight with
EAE progression, accompanied by increased corticosterone
levels (44). Furthermore, increased levels of pro-inflammatory
cytokines, including IL-6, were shown to induce acute thymic
atrophy via loss of DP thymocytes (45, 46). In fact, we observed
an increased thymic expression of Il6, Ifng, and Il17a, in
EAE animals, and this increase was more pronounced at the
onset phase of disease. These possible mechanisms could be
contributing to the thymic atrophy and loss of DP thymocytes
observed in this study.
Regarding thymic histology, at the onset phase of disease, the
cortical layer presented increased atrophy when compared to the
medullary layer. This is consistent with the observed decrease
in the DP population, which is the most abundant population
in the cortical layer. On the other hand, at the chronic phase,
accompanying the restitution of the thymocyte populations’
percentages, the medullary/cortical ratio was also restored to
control levels.
In terms of thymic gene expression, we found alterations
in genes related with thymocyte survival and diﬀerentiation.
IL-7 is produced by thymic stromal cells and plays a critical
role in thymocyte survival, by inducing the expression of anti-
apoptotic factors like Bcl2 (47, 48), and in the maturation of DN
cells (49). Similarly to IL-7, TGFb1 was shown to play an anti-
apoptotic role in thymocytes (50), by enhancing Bcl2 expression
levels and reducing the pro-apoptotic Bim levels (51). All these
genes were found to be up-regulated during the onset phase
of EAE, suggesting a compensatory mechanism to increase the
survival and diﬀerentiation of immature thymocytes, promote
the transition to DP thymocytes and ultimately lead to thymic
recovery. In fact, at a later disease time point, the chronic phase,
the expression levels of these cytokines were decreased, compared
to the onset phase, and, although the thymic atrophy persisted,
the percentage of the DP thymocytes was normalized.
Altogether, we describe here that the thymus presents dynamic
alterations throughout EAE development. Other studies have also
shown thymic atrophy in EAE animals, however here we describe
that thymocyte proportions are altered in a more active phase of
disease, the onset, but not during the chronic phase. In addition,
the medullary-cortical ratio is clearly altered, but only at the EAE
onset. In the future, the modulation of the corticosterone levels
and of the thymic response could help to elucidate if the thymic
alterations are solely a consequence of increased corticosterone
and/or increased production of pro-inflammatory cytokines, or
if there is a cause-consequence relation between what happens
in the CNS and in the thymus. Importantly, understanding the
thymic alterations in the MS context may help to develop new
therapeutic strategies, focused on the thymus, and that may be
able to modulate disease progression.
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